![Robert Knight](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Robert Knight is currently the Chief Medical Officer at NexImmune, Inc. Prior to this, he was the Vice President-Clinical Development at Kite Pharma, Inc. from 2020 to 2021, the Vice President-Clinical Research at Sorrento Therapeutics, Inc. from 2017 to 2020, and the Corporate Vice President at Celgene Corp.
from 2001 to 2017.
Dr. Knight received his undergraduate degree from the US Military Academy and his doctorate degree from The State University of New York.
Anciens postes connus de Robert Knight
Sociétés | Poste | Fin |
---|---|---|
KITE PHARMA INC | Corporate Officer/Principal | 01/01/2021 |
SORRENTO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2020 |
CELGENE | Corporate Officer/Principal | 01/06/2017 |
NEXIMMUNE, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Robert Knight
The State University of New York | Doctorate Degree |
US Military Academy | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
SORRENTO THERAPEUTICS, INC. | Health Technology |
NEXIMMUNE, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Celgene Corp.
![]() Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Kite Pharma, Inc.
![]() Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |